Project Grant R01HL178765
Award Date 7/20/26
Completion Date 4/30/30
Dollars Obligated $779K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,600 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental mechanisms that direct cardiac cell diversification and left ventricle morphogenesis. The research employs single-cell transcriptomic analyses and lineage tracing in mouse embryos to define the gene regulatory networks controlling how diverse cardiac cell types emerge from...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of California, San Diego $168,795 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on proteostasis in hematopoietic stem cell development. The project, titled "Proteostasis in Hematopoietic Stem Cell Development," addresses dysfunction in inherited bone marrow failure syndromes by investigating protein homeostasis disruption in...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $799,256 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiac protection through neuromodulation after myocardial infarction. The project, designated R01HL183128, will conduct research on the interplay between cardiac injury signals, brain integration, and peripheral sympathetic outflow following myocardial infarction. The work spans three...
- The National Heart, Lung, and Blood Institute awarded the University of California Irvine $235,500 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiac complications of dystrophin deficiency in female carriers of Duchenne muscular dystrophy. The research will examine how mosaic expression of dystrophin affects cardiomyocytes differentiated from human induced pluripotent stem cells of female carriers. The work will compare functional...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $531,794 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of microRNA-98-5p (mir98) in myocardial ischemia-reperfusion injury during late pregnancy. The research addresses the mechanism underlying increased myocardial infarct size in late-pregnancy rats compared to non-pregnant rats. Prior work from the recipient's laboratory demonstrated a...
- The National Heart, Lung, and Blood Institute awarded Yale University $445,000 under CFDA 93.837 (Cardiovascular Diseases Research) on August 1, 2026, to develop deuterium metabolic imaging (DMI) as a non-invasive diagnostic tool for hibernating myocardium in coronary artery disease patients. The award is classified as a Project Grant under NIH assistance type R21HL184055. The research addresses a clinical gap: roughly 4 million Americans with heart failure stemming from coronary artery...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $778,127 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL180797) to enhance lamellar body function via LRRK2 inhibition and reduce respiratory distress syndrome severity in preterm newborns. The research investigates leucine-rich repeat kinase 2 (LRRK2) inhibition as a novel therapeutic approach to enhance endogenous surfactant production in...
- The National Heart, Lung, and Blood Institute awarded $609,574 to the University of California, San Diego on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the cellular and molecular mechanisms regulating cardiac chamber morphology. The recipient is investigating how cardiomyocytes acquire distinct shapes and organizational patterns in the outer and inner curvatures of the embryonic ventricle, which establish proper cardiac chamber...